Please ensure Javascript is enabled for purposes of website accessibility

FDA Authorizes Plasma Antibodies as a COVID-19 Treatment

By Brian Orelli, PhD - Aug 24, 2020 at 9:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The authorization is light on the data.

The Food and Drug Administration (FDA) issued an emergency use authorization yesterday for the utilization of convalescent plasma as a treatment for COVID-19. Convalescent plasma contains antibodies against the novel coronavirus that causes COVID-19. The plasma is harvested from patients who have recovered from the disease.

"The FDA determined that it is reasonable to believe that COVID-19 convalescent plasma may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitalized patients," the agency said in a press release announcing the decision.

If "reasonable" doesn't sound like a ringing endorsement, that's because it isn't. The authorization is based on two small randomized clinical trials -- neither of which reached statistical significance. The authorization also included data from nonrandomized studies and data on patients treated under an expanded access program, both of which don't have a control group, making the data hard to interpret.

This is an emergency use authorization rather than a full approval because the FDA believes "COVID-19 convalescent plasma does not yet represent a new standard of care based on the current available evidence." The agency encouraged clinical trials testing convalescent plasma to continue unaltered, to gain better evidence on whether the treatment actually helps patients.

Doctors in personal protective equipment talking to a patient

Image source: Getty Images.

Over 70,000 patients have been treated with convalescent plasma, so it seems reasonable that the agency has enough data to conclude that the treatment is relatively safe. Nevertheless, there are still some risks associated with plasma transfusion, including acute lung injury, cardiac overload, reactions to the treatment, and infections from the donors.

A consortium of biotechs and pharmaceutical companies, including CSL Behring (CSLL.Y -2.09%) and Takeda Pharmaceutical (TAK -2.15%), is working on a commercial plasma-derived antibody treatment, as is Emergent BioSolutions (EBS -1.33%).

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$28.12 (-1.33%) $0.38
CSL Limited Stock Quote
CSL Limited
CSLL.Y
$101.16 (-2.09%) $-2.15
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
TAK
$13.88 (-2.15%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.